Cell Pryme-M is the one that exites me the most in short term, as if it can be incorporated via a simple manufacturing step change then we at likely to see deals relatively soon.
OmniCAR and Cell Pryme-A are 'patient touching' and therefore follow the standard Phase 1-3 requirements, albeit have read previously that the current CarT were approved after only Phase 2 due to the previously unheard of response and efficiency rates, but these platfotms are where the greatest gains will come from.
PTX Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
